RT Journal Article SR Electronic T1 Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1 JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1683 OP 1690 DO 10.21873/anticanres.14120 VO 40 IS 3 A1 HAYATO WATANABE A1 TSUTOMU HAYASHI A1 KEISUKE KOMORI A1 KENTARO HARA A1 YUKIO MAEZAWA A1 KAZUKI KANO A1 YOTA SHIMODA A1 HIROHITO FUJIKAWA A1 TORU AOYAMA A1 TAKANOBU YAMADA A1 NAOTO YAMAMOTO A1 HARUHIKO CHO A1 HIROYUKI ITO A1 MANABU SHIOZAWA A1 NORIO YUKAWA A1 SOICHIRO MORINAGA A1 TAKAKI YOSHIKAWA A1 YASUSHI RINO A1 MUNETAKA MASUDA A1 TAKASHI OGATA A1 TAKASHI OSHIMA YR 2020 UL http://ar.iiarjournals.org/content/40/3/1683.abstract AB Background: This study aimed to investigate the impact of postoperative complications (PCs) in patients with pathological stage (pStage) II or III gastric cancer (GC) who received adjuvant chemotherapy with S-1 after curative surgery. Patients and Methods: Altogether, data for 226 patients were examined retrospectively. The relationship between PCs and clinicopathological features and survival were examined. Results: Recurrence-free survival was significantly worse in the group with PCs than in the PC-negative group. On multivariate analysis, having PCs of grade 2 or more was an independent risk factor for recurrence (hazard ratio=1.721; 95% confidence intervaI=1.014-2.920; p=0.044). In addition, for each pStage analysis, having PCs of grade 2 or more was a risk factor for recurrence even in patients with pStage II GC. Conclusion: PC of grade 2 or more was an independent risk factor for recurrence in patients with pStage II GC who received adjuvant chemotherapy with S-1 after curative gastrectomy. Thus, for patients with PCs, even for those with pStage II GC, more effective adjuvant chemotherapy, such as S-1 plus docetaxel, may be needed.